Etop Ibcsg Partners Foundation

This trial tests three different schedules of the chemotherapy drug nab-paclitaxel (Abraxane) in women with HER2-negative metastatic breast cancer. The goal is to find a schedule that allows patients to stay on treatment longer, potentially improving progression-free survival, wh…

This trial tests two drugs, degarelix and triptorelin, in premenopausal women with hormone-sensitive breast cancer. Both drugs temporarily stop the ovaries from making estrogen, which can fuel tumor growth. Women receive one of the drugs along with the hormone therapy letrozole f…

This phase III trial tests whether taking letrozole continuously for five years is better than taking it in cycles with breaks, for postmenopausal women who have already had 4 to 6 years of hormone therapy for early-stage, hormone-receptor-positive breast cancer. Letrozole works …

This phase II trial is testing whether a combination of palbociclib (a targeted pill), hormone therapy, and HER2-targeted drugs can shrink early-stage breast tumors as effectively as standard chemotherapy before surgery. Postmenopausal women with hormone receptor-positive, HER2-p…

This study looked at whether shutting down the ovaries (ovarian suppression) combined with hormone therapy (tamoxifen or exemestane) could better prevent breast cancer from coming back in premenopausal women with hormone-sensitive breast cancer. Over 3,000 women who had surgery t…

This trial investigates whether combining two targeted drugs—erlotinib and bevacizumab—can help people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see if the combination extends the time before the cancer grows or spreads. Participant…

This phase 2 trial investigates whether afatinib, an oral targeted therapy, can control advanced non-small cell lung cancer (NSCLC) that carries a specific HER2 exon 20 mutation. Participants have already received prior chemotherapy and have stage IIIB or IV disease. The study me…

This trial is testing whether a blood test called VeriStrat can help choose between two drugs for people with advanced squamous non-small cell lung cancer that has progressed after initial chemotherapy. Participants are grouped by their VeriStrat result (good or poor) and then ra…

This study tested whether adding bevacizumab to osimertinib helps people with advanced non-small cell lung cancer that has a specific genetic change (EGFR and T790M mutations). 155 adults who had already tried other treatments took part. The main goal was to see if the combinatio…

This trial is testing whether combining palbociclib and fulvestrant can help postmenopausal women with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to prior treatments. The study aims to see how long the cancer stays under control and to look …

This trial is investigating whether adding the immunotherapy drug nivolumab to the usual chemotherapy and radiation can improve outcomes for people with stage III non-small cell lung cancer. The study will measure how well the combination works and how tolerable the side effects …

This trial is investigating whether adding two immunotherapy drugs, nivolumab and ipilimumab, after standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. Even though initial treatment often works well, the cancer frequently returns within …

This trial compares two treatments for people with advanced malignant pleural mesothelioma, a cancer of the lining of the lungs, that has progressed after initial chemotherapy. Half of the participants receive pembrolizumab, an immunotherapy that helps the immune system fight can…

This study tested a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The trial enrolled 95 adults and gave them two different combinations of immunotherapy (atezolizum…

This study tested whether adding the immunotherapy drug atezolizumab to standard treatment (bevacizumab plus chemotherapy) helps people with advanced malignant pleural mesothelioma live longer. The trial involved 400 adults whose cancer could not be removed by surgery. Researcher…

This study tested a new drug called giredestrant, alone or with triptorelin, against a standard treatment (anastrozole plus triptorelin) in 231 premenopausal women with early-stage, hormone-sensitive breast cancer. The goal was to see how well the drugs slow tumor growth before s…

This study looked at two different hormone therapy combinations for premenopausal women with a type of breast cancer that grows in response to hormones. Over 2,600 women who had surgery to remove their cancer were randomly assigned to receive either exemestane plus triptorelin or…